The Heterogeneity of Prostate Cancer: Implications for Research
- 26 Downloads
Cancer does not treat all its victims equally. Some progress rapidly from diagnosis to death; in others the disease advances almost imperceptibly. This variation in malignant expression is certainly apparent from one type of cancer to another. In the case of melanoma and basal cell carcinomas of the skin, for example, even the same tumor type may act differently in two patients. As a model of heterogeneity, prostate cancer is of particular importance because of its variable behavior in patients belonging to various minorities (Young et al. 1984).
KeywordsProstate Cancer Basal Cell Carcinoma Osseous Metastasis American Black Malignant Tumor Type
Unable to display preview. Download preview PDF.
- Dayal HH, Chiu C: Factors associated with racial differences in survival for prostatic carcinoma. J Clin Res 1982; 35:553–560.Google Scholar
- Gleason DF, Mellinger GT, and The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 3:58–64.Google Scholar
- Haenszel W, Kurihara M: Studies of Japanese migrants I. Mortality from cancer and other diseases among Japanese in the United States. JNCI 1960; 40:43–68.Google Scholar
- Johnson DE, Swanson DA, von Eschenbach AC. Tumors of the genitourinary tract. In Tanagho EA, McAninch JW, eds, General Urology, 12th Ed. Norwalk: Appleton & Lange, 1988.Google Scholar
- Logothetis CJ, Samuels ML, von Eschenbach AC, et al: Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate with a note on the staging metastatic prostate cancer. J Clin Onocol 1983; 1:368–379.Google Scholar
- Rose DP: The biochemical epidemiology of prostatic carcinoma. In: Dietary Fat and Cancer, New York: Alan R Liss, 1986, pp 43–68.Google Scholar